Gastrointestinal tumours, non-colorectal
LBA56 - Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study
Thomas Seufferlein, et al.
Perioperative CTX did not reach a DFS-R at 18mo of 55% in the mITT population. Neoadjuvant CTX showed high R0-RR and long DFS in the ITT-P and could be applied to more patients than adjuvant CTX. Neoadjuvant CTX is proposed to be a new standard for trials also in rPDAC.
LBA57 - Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)
Thierry Conroy, et al.
With ≥5 yr fu, updated results of PRODIGE 24/CCTG PA6 trial confirm that adjuvant FFX yields significantly longer DFS, OS, MFS and SS compared to Gem.
1376O - The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): A randomized multicentre phase III trial (GASTRIPEC-I-trial)
Beate Rau, et al.
The study showed no difference in OS in pts treated with CRS ± HIPEC. However, the PFS and MFS were significantly better in the CRS+H group. Therefore, further investigations seem worthwhile. Additional HIPEC did not compromise patient’s safety.
1372O - CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system
Changsong Qi, et al.
CT041 showed acceptable safety profile and promising anti-tumor activities in patients with refractory CLDN18.2+ cancers of digestive system. In patients with GC who have failed at least 2 prior lines of therapy, CT041 displayed a significantly improved efficacy compared to historical data.